INZ-701 is under clinical development by Inozyme Pharma and currently in Phase II for Rickets. According to GlobalData, Phase II drugs for Rickets have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how INZ-701’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

INZ-701 overview

INZ-701 is under development for the treatment of rare genetic diseases of ENPP1 deficiency (generalized arterial calcification infancy (GACI) and autosomal recessive hypophosphatemic rickets type II (ARHR2), rare genetic diseases of ABCC6 Deficiency (pseudoxanthoma elasticum or PXE), calciphylaxis, end-stage kidney disease (ESKD) and diseases of neointimal proliferation. It is administered through subcutaneous route. 

Inozyme Pharma overview

Inozyme Pharma is a clinical-stage rare disease biopharmaceutical company that develops novel therapeutics for the treatment of rare genetic diseases of ENPP1, ABCC6 deficiencies and impacting the vasculature, soft tissue and skeleton. It is headquartered in Boston, Massachusetts, the US.

For a complete picture of INZ-701’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.